The addition of albumin-bound paclitaxel (nab-paclitaxel) to the treatment standard gemcitabine significantly lengthened survival in patients with metastatic pancreatic cancer
Jill Stein
Advertisement
Articles by Jill Stein
Older patients with advanced hematologic malignancies who receive a minimally toxic nonmyeloablative regimen before allogeneic HCT have favorable OS and PFS rates.
New findings demonstrate a recent increase in the annual completion rates of vaccination against human papillomavirus (HPV) infection.
Advertisement
Latest Updated Articles
- Nab-Paclitaxel Boosts Survival in Pancreatic Cancer
Published: January 10th 2014 | Updated:
- HPV Vaccination Completion Rates Increase, but Gaps Remain
Published: December 2nd 2011 | Updated:
- Nonmyeloablative Conditioning Before Cell Transplantation Shows Potential in Older Patients With Hematologic Malignancies
Published: January 26th 2012 | Updated:
Advertisement
Advertisement
Trending on Oncology Nursing News
1
How Using Gender-Neutral Language Can Open Goals of Care Conversations
2
The “Owners” and “Managers” in the Peer-to-Peer Process: What an APP Should Know
3
Physical Activity Supervision Does Not Up QOL in Metastatic Cancer
4
